Pfizer: MONeT Study Topline Data Positive for Abrysvo in Adults Aged 18 to 59 Years at High Risk for RSV-LRTD
Pfizer plans to submit the phase 3 MONeT data to regulatory bodies in support of an expanded label for Abrysvo to include adults aged 18 to 59, the company said.
Semaglutide 2.4 mg Improves Functional Status, Body Weight in Adults with HFpEF, Obesity, T2D
ACC.24: Results of STEP HFpEF DM showed significant improvement in quality of life measures among adults with obesity-related HFpEF and type 2 diabetes.
Zilebesiran Reduces SBP by Up to 14 mm Hg on Background SOC in Uncontrolled Hypertension: KARDIA-2
ACC.24: Zilebesiran led to clinically and statistically significant reductions in SBP on top of either a diuretic, CCB, or ARB; SQ dosing is every 3-6 months.
Secondary CVD Prevention Requires Much More than "Usual Care," Says Michael Koren, MD,
ACC.24: Individuals with ASCVD not at target LDL-C on maximum statin therapy need immediate intervention and one that works, said V-INITIATE primary investigator.
The Inclisiran Impact on PCSK9: A Primary Care Primer
ACC.24: Michael Koren, MD, highlights how the nonstatin lipid-lowering medication's mechanism of action against PCSK9 differs from others in the category.
Michael J Koren, MD, Reviews Success of "Inclisiran First" Strategy and Implications for Clinical Practice
ACC.24: The primary investigator of the VICTORION-INITIATE study explains why new strategies are needed to accelerate LDL-C lowering in high-risk individuals.
"Inclisiran First" Strategy Leads to 60% Reduction in LDL-C vs 7% for Usual Care: VICTORION-INITIATE Findings
ACC. 24: A structured, systematic approach to lipid-lowering therapy in secondary prevention is needed to ensure targets are met and met swiftly, said researchers.
Bempedoic Acid Reduces CV Risk in Latinx Population with Statin-Intolerance: Daily Dose
Your daily dose of the clinical news you may have missed.
Optimal Cardioprotective BMI for Adults with Type 2 Diabetes Could Vary by Age, New Study Suggests
In a population cohort of adults with T2D, a BMI above "normal" range appeared more likely to protect against CV death in those older than age 65 years than those younger.
7 Drugs Approved for Primary Care: Q1 2024
The end of another quarter means a new list of FDA-approved drugs for conditions treated in primary care. Are you up-to-date? Click through to find out.
Older, Mentally Altered Adults at Greatest Risk for Inappropriate Diagnosis of CAP
More than 1 in 10 older adults were misdiagnosed with community-acquired pneumonia and nearly all were treated with a full course of antibiotics, a new study found.
Primary Care-Based Injury Prevention Program Found to Reduce Pediatric Injuries in New Study
The program, when implemented with support of resident training and tangible tools, reduced parent-reported injuries throughout the first 2 years of life.
T2D Remission via Lifestyle Intervention Reduces CVD, CKD Risk: Daily Dose
Nontraditional Risk Factors More Likely to Cause Stroke in Young Adults, Study Finds
Migraine was the most important nontraditional risk factor linked to stroke in adults aged 18 to 34 years and should be considered in evaluation for an event.
ARS Pharma Submits Response to FDA Complete Response Letter for neffy (epinephrine nasal spray)
Positive findings from a repeat dosing study of neffy under nasal allergen challenge conditions will support a potential PDUFA date of October 2, 2024, the company said.
FDA Clears First AI-Based Algorithm to Detect Heart Failure during Routine Exams
The Low EF AI is designed to detect low ejection fraction in 15 seconds during a primary care exam.
New Follow-Up Measure After Stool-Based CRC Test Could Improve Colonoscopy Rates, Outcomes
The quality performance measure is viable and reliable and could help improve early CRC detection rates via timely colonoscopy following abnormal stool-based test.
FDA Approves Fixed-Dose Macitentan/Tadalafil Tablets for PAH: Daily Dose
Atogepant Found More Effective for Migraine Prevention vs Rimegepant in New Analysis
Atogepant was associated with fewer monthly migraine days, fewer acute medication use days, and greater QoL compared with rimegepant after 12 weeks.
Vaping Associated with Increased Risk of Heart Failure, According to New Research
ACC.24: Data showed that individuals who used e-cigarettes were approximately 19% more likely to develop heart failure compared with those who had never vaped.
